Volver a Agenda
Session Chair(s)
Charles A. Stevens, JD, MBA
Vice President and General Manager
PAREXEL Consulting, United States
Learning Objective : Explain how rare disease and orphan products are changing payer regulator views on how to manage these products; Discuss how patient subpopulations, even within rare disorders, can impact overall product value and access; Describe the importance that budget impact models have even in rare disorders.
Speaker(s)
Panelist
Igor Gorlach
Foley Hoag LLP, United States
Associate
Panelist
Jim Long
BioSolutia, United States
Co-Founder and Principal
¿Tiene una cuenta?